Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Non-linear mixed effects modeling (NLMEM) is the most common statistical model used in population analysis.

Bioavailability 132

Bioavailability Bioequivalency Production In-Vivo 132

Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses.

Bioequivalency 156

Bioequivalency Genotoxicity Bioavailability Production 156

Camargo

SEPTEMBER 30, 2021

The drug development process is a long journey, beginning with drug discovery, moving through nonclinical and clinical studies, and ultimately culminating in regulatory approval. Nonclinical studies are not a mere tick-box exercise in a drug development program.

Bioavailability 177

Bioavailability Development Compliance Manufacturing 177

The Pharma Data

MARCH 8, 2021

The primary efficacy objective was reduction in time to viral negativity measured by reverse transcriptase polymerase chain reaction (RT-PCR) analysis of nasopharyngeal swabs. Animals were administered molnupiravir for longer and at higher doses (mg/Kg) than those employed in human studies.

Genotoxicity 63

Genotoxicity Bioavailability In-Vivo RNA 63

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., in a statement. . Genesis went public on December 2 in a round of $52 million Series A financing led by Rock Springs Capital.

Genotype 52

Genotype Bioavailability In-Vivo Protein 52

The Pharma Data

OCTOBER 21, 2020

Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer. Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial for advanced solid tumors in 2021. Cyclin-dependent kinase 9 (CDK9) is an important transcriptional co-factor of MYC, a well-known driver of cancer that is dysregulated in a significant proportion of solid tumors.

Bioavailability 40

Bioavailability In-Vivo In-Vitro Clinical Trials 40